3 Citaten (Scopus)
31 Downloads (Pure)


Recent advances in the manufacturing, modification, purification and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2-targeting mRNA-based vaccines has highlighted the advances of this technology. Offering rapid and straightforward manufacturing, clinical safety and versatility, this paves the way for RNA therapeutics to expand into cancer immunotherapy. Together with ongoing trials on RNA cancer vaccination and cellular therapy, RNA therapeutics could be introduced into clinical practice, possibly stewarding future personalized approaches. In the present review, we discuss recent advances in RNA-based immuno-oncology together with an update on ongoing clinical applications and their current challenges.

Originele taal-2English
Pagina's (van-tot)3929-3939
Aantal pagina's11
TijdschriftClinical Cancer Research
Nummer van het tijdschrift18
Vroegere onlinedatum2022
StatusPublished - 15 sep 2022

Bibliografische nota

©2022 The Authors; Published by the American Association for Cancer Research.


Duik in de onderzoeksthema's van 'RNA in cancer immunotherapy: unlocking the potential of the immune system'. Samen vormen ze een unieke vingerafdruk.

Citeer dit